Buspirone

Generic Name: Buspirone

Brand Names: Buspar

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₃₁N_₅O_₂

CAS Number: 36505-84-7

Unique Ingredient Identifier: TK65WKS8HL

Background: Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic drugs. Unlike many drugs used to treat anxiety, buspiro...

Indication: Indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety.

Associated Conditions: Anxiety Disorders, Depression

Associated Therapies: -

Clinical Trials

Long Term Effect of Buspirone on Esophageal Function and Esophageal Symptoms in Patients With Systematic Sclerosis (SSc)

Early Phase 1

Completed

Conditions: Systemic Sclerosis

Interventions: Drug: buspirone

First Posted Date: 2015-02-16

Last Posted Date: 2016-10-24

Lead Sponsor: Laikο General Hospital, Athens

Target Recruit Count: 22

Registration Number: NCT02363478

Locations: 🇬🇷
Academic Department of Gastroenterology, Laikon GH, Athens, Greece

Spinal Cord Neuromodulation for Spinal Cord Injury

Phase 1

Active, not recruiting

Conditions: Tetraparesis
Tetraplegia
Cervical Spinal Cord Injury

Interventions: Device: Epidural Stimulation
Drug: Buspirone

First Posted Date: 2014-12-09

Last Posted Date: 2023-05-19

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 12

Registration Number: NCT02313194

Locations: 🇺🇸
UCLA, Los Angeles, California, United States

Randomized，Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder

Phase 4

Conditions: Major Depression Disorder

Interventions: Drug: Buspirone
Drug: Paroxetine

First Posted Date: 2014-10-23

Last Posted Date: 2014-10-23

Lead Sponsor: Si Tianmei

Target Recruit Count: 240

Registration Number: NCT02273154

Locations: 🇨🇳
Henan mental health center, Xinxiang, Henan, China
🇨🇳
Institute of mental health, Peking University, Beijing, Beijing, China
🇨🇳
Wuhan mental health center, Wuhan, Hubei, China

and more 3 locations

Efficacy Study of Abdominal Massage Therapy to Treat Generalized Anxiety Disorder of Deficiency of Both Heart and Spleen Type

Not Applicable

Conditions: Anxiety Disorders

Interventions: Other: Abdominal Massage Therapy
Drug: Buspirone

First Posted Date: 2014-07-10

Last Posted Date: 2014-09-03

Lead Sponsor: Sun Qing

Target Recruit Count: 140

Registration Number: NCT02186366

Locations: 🇨🇳
The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, Tianjin, China

Buspirone, Stress, and Attentional Bias to Marijuana Cues

Phase 2

Completed

Conditions: Cannabis Use Disorder

Interventions: Drug: Placebo
Drug: Buspirone

First Posted Date: 2014-05-07

Last Posted Date: 2017-06-02

Lead Sponsor: The University of Texas Health Science Center, Houston

Target Recruit Count: 45

Registration Number: NCT02132832

Locations: 🇺🇸
University of Texas Health Science Center - Houston, Houston, Texas, United States

An Open-Label Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders

Not Applicable

Active, not recruiting

Conditions: Autism Spectrum Disorders
Anxiety

Interventions: Drug: Buspirone

First Posted Date: 2013-05-09

Last Posted Date: 2024-06-28

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 9

Registration Number: NCT01850355

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Cooling Plus Best Medical Treatment Versus Best Medical Treatment Alone for Acute Ischaemic Stroke

Phase 3

Terminated

Conditions: Acute Ischemic Stroke

Interventions: Device: Hypothermia
Drug: Buspirone
Drug: Pethidine

First Posted Date: 2013-04-16

Last Posted Date: 2019-10-02

Lead Sponsor: University of Erlangen-Nürnberg Medical School

Target Recruit Count: 98

Registration Number: NCT01833312

Locations: 🇩🇪
Department of Neurology, University Hospital Erlangen, Erlangen, Germany

Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression

Not Applicable

Recruiting

Conditions: Traumatic Brain Injury

Interventions: Drug: Placebo
Drug: Buspirone

First Posted Date: 2013-04-01

Last Posted Date: 2024-02-14

Lead Sponsor: Indiana University

Target Recruit Count: 74

Registration Number: NCT01821690

Locations: 🇺🇸
Indiana University and Rehabilitation Hospital of Indiana, Indianapolis, Indiana, United States

Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET

Phase 1

Completed

Conditions: Smoking Cessation
Tobacco Use Cessation

Interventions: Drug: Buspirone
Drug: Placebo

First Posted Date: 2012-10-04

Last Posted Date: 2014-06-04

Lead Sponsor: Centre for Addiction and Mental Health

Target Recruit Count: 6

Registration Number: NCT01699828

Locations: 🇨🇦
Center for Addiction and Mental Health, Toronto, Ontario, Canada

Study of Buspirone for Relapse-Prevention in Adults With Cocaine Dependence

Phase 2

Completed

Conditions: Cocaine Dependence

Interventions: Drug: Placebo
Drug: Buspirone

First Posted Date: 2012-07-16

Last Posted Date: 2015-01-07

Lead Sponsor: University of Cincinnati

Target Recruit Count: 62

Registration Number: NCT01641159

Locations: 🇺🇸
Maryhaven Inc, Columbus, Ohio, United States
🇺🇸
Penn Presbyterian, Philadelphia, Pennsylvania, United States
🇺🇸
Addiction Medicine Services, Pittsburgh, Pennsylvania, United States

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy